Skip to main content
. Author manuscript; available in PMC: 2019 Jan 30.
Published in final edited form as: Biochemistry. 2018 Jan 19;57(4):429–440. doi: 10.1021/acs.biochem.7b01022

Table 1.

Characteristics of PARP 1 inhibitors in clinical development.

PARP1 inhibitor Company IC50 (nm) Route Clinical trial (phase)
Olaparib (AZD-2281) AstraZeneca PARP1=5.0
PARP2=1.0		 Oral

  1. Germline BRCA-mutated advanced ovarian cancer (approved);

  2. Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (approved)
Rucaparib Clovis Oncology PARP1=1.4 Oral

  1. Deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer (approved);

  2. Metastatic castration-resistant prostate cancer (III)
Niraparib Tesaro PARP1=3.8
PARP2=2.1		 Oral

  1. Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (approved);

  2. Platinum sensitive ovarian cancer (III)
Talazoparib Pfizer PARP1=0.57 Oral

  1. Recurrent stage IV squamous cell lung cancer (II/III);

  2. Men With DNA repair defects and metastatic castration-resistant prostate cancer (II)
Veliparib (ABT-888) Abbvie PARP1=5.2
PARP2=2.9		 Oral

  1. Metastatic pancreatic cancer (II);

  2. Stage IV triple-negative and/or BRCA mutation-associated breast cancer (II)